LivaNova's VNS Therapy for Drug-Resistant Epilepsy Procedures Receives Increased Provider Reimbursement from U.S. Centers for Medicare & Medicaid Services

– New patient implants assigned to New Technology Ambulatory Payment Classification 1580 – End-of-service procedures elevated to Level 5 APC – Effective Jan. 1, 2026, will improve economics for hospitals performing